One-year follow-up of a new posterior chamber toric phakic intraocular lens implantation for moderate-to-high myopic astigmatism
International Ophthalmology, cilt.41, sa.9, ss.2941-2949, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 9
- Basım Tarihi: 2021
- Doi Numarası: 10.1007/s10792-021-01853-7
- Dergi Adı: International Ophthalmology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2941-2949
- Anahtar Kelimeler: Toric phakic intraocular lens, PIOL, Myopia, Astigmatism, High myopic astigmatism
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To investigate refractive and visual outcomes as well as rotational stability following implantation of Eyecryl phakic toric intraocular lens (pIOL) for moderate-to-high myopic astigmatism. Methods: The efficacy, safety, predictability, stability, and adverse events of Eyecryl toric pIOL were evaluated in patients with spherical refraction from − 4.50 to − 18.50 diopters (D) and cylindrical refraction from − 0.50 to − 5.50 D. Results: This study included 60 eyes of 31 patients. The mean manifest refraction spherical equivalent (MRSE) dropped from − 10.45 ± 2.74 D preoperatively to − 0.34 ± 0.51 D and − 0.40 ± 0.56 D at 6 and 12 months postoperatively, respectively. There was an 81% decrease in astigmatism after surgery. The safety and efficacy of indices were 1.36 ± 0.43 and 1.20 ± 0.32. At the final follow-up, the rate of eyes within ± 1.00 D and ± 0.50 D of the desired MRSE were 85% and 68.33%, respectively. Vision-threatening complications were not observed during the follow-up. Conclusions: The implantation of pIOL was effective, safe, and predictable in patients with moderate-to-high myopic astigmatism during 1-year follow-up.